Steris (STE Quick QuoteSTE - Free Report) reported $1.28 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 0.4%. EPS of $2.03 for the same period compares to $2.00 a year ago.

The reported revenue represents a surprise of +1.47% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being $2.01, the EPS surprise was +1.00%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Healthcare

  : $901.22 million versus the three-analyst average estimate of $881.76 million. The reported number represents a year-over-year change of +10.1%.

• Revenues- Life Sciences

  : $128.48 million versus $132.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change.

• Revenues- Applied Sterilization Technologies

  : $249.80 million compared to the $246.82 million average estimate based on three analysts. The reported number represents a change of +7.2% year over year.

• Revenues- Life Sciences- Capital equipment

  : $26.48 million versus $36.72 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.6% change.

• Revenues- Life Sciences- Service

  : $32.18 million compared to the $37.21 million average estimate based on two analysts. The reported number represents a change of -16.9% year over year.

• Revenues- Healthcare Products- Service

  : $343.23 million versus the two-analyst average estimate of $332.87 million. The reported number represents a year-over-year change of +14.2%.

• Revenues- Healthcare Products- Capital equipment

  : $214.64 million versus $232.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -9.9% change.

• Revenues- Healthcare Products- Consumables

  : $343.35 million compared to the $306.70 million average estimate based on two analysts. The reported number represents a change of +22.5% year over year.

• Revenues- Life Sciences- Consumables

  : $69.82 million compared to the $60.60 million average estimate based on two analysts. The reported number represents a change of +13.2% year over year.

• Operating income / (loss)- Healthcare

  : $216.89 million versus the two-analyst average estimate of $204.69 million.

• Operating income / (loss)- Corporate and Other

  : -$101.75 million compared to the -$80.19 million average estimate based on two analysts.

• Operating income / (loss)- Applied Sterilization Technologies

  : $117.71 million compared to the $114.56 million average estimate based on two analysts.

View all Key Company Metrics for Steris here>>>

Shares of Steris have returned +8.2% over the past month versus the Zacks S&P 500 composite's -6.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.